Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label Phase II study.

MLA

Chari, Ajai, et al. “Subcutaneous Daratumumab plus Standard Treatment Regimens in Patients with Multiple Myeloma across Lines of Therapy (PLEIADES): An Open-Label Phase II Study.” British Journal of Haematology, vol. 192, no. 5, Mar. 2021, pp. 869–78. EBSCOhost, https://doi.org/10.1111/bjh.16980.

APA

Chari, A., Rodriguez-Otero, P., McCarthy, H., Suzuki, K., Hungria, V., Sureda Balari, A., Perrot, A., Hulin, C., Magen, H., Iida, S., Maisnar, V., Karlin, L., Pour, L., Parasrampuria, D. A., Masterson, T., Kosh, M., Yang, S., Delioukina, M., Qi, M., … Touzeau, C. (2021). Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label Phase II study. British Journal of Haematology, 192(5), 869–878. https://doi.org/10.1111/bjh.16980

Chicago

Chari, Ajai, Paula Rodriguez-Otero, Helen McCarthy, Kenshi Suzuki, Vania Hungria, Anna Sureda Balari, Aurore Perrot, et al. 2021. “Subcutaneous Daratumumab plus Standard Treatment Regimens in Patients with Multiple Myeloma across Lines of Therapy (PLEIADES): An Open-Label Phase II Study.” British Journal of Haematology 192 (5): 869–78. doi:10.1111/bjh.16980.